

Whole sample (N=250)	TOXO- (N=66. 26.4%)	TOXO+ (N=184. 73.6%)	Multivariate Model 1				Multivariate Model 2				Multivariate Model 3					
			Global symptomatology				Specific symptoms				Peripheral inflammation					
			N or mean (% or SD)	N or mean (% or SD)	N or mean (% or SD)	univariate p value	aOR	IC95% %	IC95% % adjusted p value	aOR	IC95% %	IC95% % adjusted p value	aOR	IC95% %	IC95% % adjusted p value	
Sociodemographic and illness variables																
Age (years)	32.0(8.6)	32.0(8.3)	32.0(8.8)	0.86	0.9	0.9	1.0	0.84	0.9	0.9	1.0	0.56	1.0	0.9	1.0	0.85
Gender (male)	184(73.6%)	47(71.2%)	13(74.5%)	0.61	1.0	0.5	2.1	0.81	1.4	0.5	3.5	0.44	1.1	0.5	2.1	0.74
Education level (years)	12.5(2.5)	12.7(2.6)	12.4(2.5)	0.40												
Age at illness onset (years)	21.8(6.7)	22.1(6.7)	21.6(6.8)	0.74												
Age at first treatment (years)	23.1(6.0)	22.9(5.2)	23.2(6.4)	0.95												
Illness duration (years)	10.6(7.1)	10.4(7.1)	10.7(7.2)	0.81												
Addictions																
Current cannabis use disorder	21(8.4%)	5(7.6%)	16(8.7%)	0.78												
Current alcohol use disorder	20(8.0%)	5(6.1%)	16(8.7%)	0.50												
Current daily tobacco smoking	129(52.7%)	30(47.6%)	99(54.4%)	0.35												
Clinical symptomatology																
PANSS total score	71.1(19.4)	64.4(15.2)	73.5(20.2)	0.001									1.1	1.1	1.1	0.004
PANSS positive subscore	9.5(4.3)	8.9(3.4)	9.7(4.6)	0.44												
PANSS negative subscore	16.7(6.5)	14.7(6.3)	17.5(6.4)	0.003	1.1	1.1	1.1	0.04								
PANSS disorganized subscore	8.2(3.8)	7.4(3.4)	8.5(4.0)	0.09	0.9	0.8	1.0	0.70								
PANSS excited subscore	5.5(2.2)	4.7(1.5)	5.8(2.4)	<0.0001	1.3	1.1	1.6	0.01								
PANSS depressive subscore	7.8(3.2)	7.8(3.4)	7.8(3.2)	0.90												
Suicide attempt in the last 12 months	9(3.8%)	2(3.0%)	7(4.0%)	0.72												
Number of lifetime psychotic episodes	3.1(3.0)	3.3(3.7)	3.0(2.6)	0.68												
Number of lifetime thymic episodes	1.5(2.3)	1.3(1.8)	1.6(2.5)	0.51												
Paranoid delusion	99(45.2%)	79(49.4%)	20(33.9%)	0.04					0.5	0.1	1.4	0.20				

Reference delusion	60(27.6%)	23(39.7%)	37(23.3%)	0.01		3.6	1.2	10.6	0.01
Grandiosity delusion	19(8.5%)	5(8.5%)	14(8.5%)	0.98					
Somatic delusion	29(12.9%)	8(13.3%)	21(12.8%)	0.92					
Mystic delusion	29(13.0%)	8(13.8%)	21(12.7%)	0.83					
Auditory hallucinations	68(31.3%)	18(31.6%)	50(31.3%)	0.96					
Cenesthetic hallucinations	41(18.4%)	12(20.3%)	29(17.7%)	0.65					
Visual hallucinations	33(14.5%)	5(8.1%)	28(12.3%)	0.09		0.3	0.1	1.6	0.18
Desorganized behavior	28(12.6%)	3(5.0%)	25(15.3%)	0.04		1.0	0.1	6.6	0.92
Blunted affect	109(51.4%)	24(44.4%)	85(53.8%)	0.23					
Alogia	58(26.9%)	1(1.7%)	57(36.3%)	<0.0001		16.7	2.0	134.7	0.008
Avolia	118(54.9%)	20(36.4%)	98(61.3%)	0.001		1.4	0.6	3.2	0.41
Chronic peripheral inflammation (hsCRP≥3 mg/L)	55(22.0%)	5(7.6%)	50(27.2%)	0.001			3.8	1.4	10.3
									0.007
Treatments									
SGA	184(91.5%)	49(87.5%)	135(93.1%)	0.20					
FGA	52(25.9%)	14(25.0%)	38(26.2%)	0.86					
Chlorpromazine equivalent	602.7(607.2)	543.5(441.4)	622.4(653.6)	0.87					
Extrapyramidal symptoms	0.2(0.3)	0.1(0.1)	0.2(0.4)	0.03	7.4	1.6	34.4	0.01	11.5
Antidepressants	76(37.4%)	21(37.5%)	55(37.4%)	0.99					
Benzodiazepine	55(26.6%)	12(21.1%)	43(28.7%)	0.27					
Mood stabilizers	35(17.3%)	11(19.6%)	24(16.4%)	0.59					
Anticholinergic drugs	51(25.2%)	16(28.6%)	35(24.%)	0.50					

Table 1. Associations between toxoplasmosis status, clinical characteristics and peripheral inflammation in a sample of 250 community-dwelling stabilized outpatients with schizophrenia. Univariate and multivariate analyses. Extrapyramidal symptoms were measured with the Simpson and Angus scale. Significant associations are in bold.

PANSS Positive and negative Syndrome Scale. FGA First Generation Antipsychotic. SGA second generation antipsychotic. CPZeq Chlorpromazine equivalent.

PANSS total score has not been included in model 1 and 2 (model 1 including PANSS subscores and model 2 assessing specific symptoms already included in the PANSS score)